RETROVIRAL PHARMACEUTICALS
DEAD

Serial Number

97872878

Owner

Retroviral Therapeutics LLC

Attorney

Thomas E. Kenney

Filing Date

Apr 4, 2023

Add to watchlist:

No watchlists yet
View on USPTO

RETROVIRAL PHARMACEUTICALS Trademark

Serial Number: 97872878

RETROVIRAL PHARMACEUTICALS is a trademark filed by Retroviral Therapeutics LLC on April 4, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Retroviral Therapeutics LLC (5 trademarks)

12 Smith Hill Road
Lincoln, MA 01773

Entity Type: 16

Trademark Details

Filing Date

April 4, 2023

Registration Date

Not Registered

Goods & Services

Vaccines; Biological preparations for the treatment of diseases, disorders and illnesses, namely, cancer, osteoporosis, kidney diseases, liver diseases, viral infections, infectious diseases, and retroviruses; Medical preparations for the treatment of diseases, disorders and illnesses, namely, infectious diseases, cancer, osteporosis, kidney diseases, liver diseases, viral infections, and for use in oncology and retroviruses; Pharmaceutical preparations for the treatment and prevention of diseases, disorders and illnesses, namely, cancer, osteoporosis, kidney diseases, liver diseases, viral infections, infectious diseases, and retroviruses; Therapeutic pharmaceutical for the treatment of diseases, disorders and illnesses, namely, cancer, osteoporosis, kidney diseases, liver diseases, viral infections, infectious diseases, and retroviruses; Therapeutic vaccines

Bacteriological research and analysis; Bacteriological research and testing; Consulting services for others in the field of design, planning, and implementation project management of scientific research and clinical trials involving viruses used for clinical and treatment purposes; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific and technological services, namely, design, engineering, research, development and testing in the field of immunopharmaceuticals and vaccines involving viruses used for clinical and treatment purposes

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Aug 29, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Aug 29, 2024 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
May 15, 2024 GNFN
FINAL REFUSAL E-MAILED
May 15, 2024 GNFR
FINAL REFUSAL WRITTEN
May 15, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 10, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 10, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 10, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 10, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 10, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 10, 2024 CNRT
ASSIGNED TO EXAMINER
Dec 29, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 27, 2023 NWOS
NEW APPLICATION ENTERED
Apr 7, 2023 NWAP